MRNAHealthcare · BiotechnologyThe 23 Wall Street analysts covering Moderna, Inc. hold a median 12-month price target of $125 — -43.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 78 of 100 as at 28 Oct 2026 — inside the top quartile. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Moderna, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (99): The shares have been drifting up relative to others.
Issuance (27): The company has been issuing shares or taking on financing, diluting existing holders.
Size (3): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on MRNA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −43.9% from it.
Of the 20 most recent actions, 9 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 Oct 2026 | William Blair | Downgrade | Market Perform | — |
| 26 Oct 2026 | Piper Sandler | Reiterates | Overweight | $167 → $230 |
| 21 Oct 2026 | TD Cowen | Maintains | Hold | $40 → $90 |
| 15 Oct 2026 | Goldman Sachs | Maintains | Neutral | $120 → $137 |
| 7 Oct 2026 | Morgan Stanley | Maintains | Equal-Weight | $89 → $95 |
| 7 Oct 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 30 Sept 2026 | Citigroup | Downgrade | Sell | $60 → $80 |
| 30 Sept 2026 | Citigroup | Downgrade | Sell | — |
| 3 Sept 2026 | Rothschild & Co | Downgrade | Sell | $40 → $81 |
| 3 Sept 2026 | Rothschild & Co | Downgrade | Sell | — |
| 28 Aug 2026 | Argus Research | Upgrade | Buy | $180 |
| 28 Aug 2026 | Argus Research | Upgrade | Buy | — |
| 25 Aug 2026 | Wolfe Research | Upgrade | Peer Perform | — |
| 25 Aug 2026 | Wolfe Research | Upgrade | Peer Perform | — |
| 24 Aug 2026 | Barclays | Maintains | Equal-Weight | $48 → $125 |
| 24 Aug 2026 | Barclays | Maintains | Equal-Weight | — |
| 21 Aug 2026 | JP Morgan | Maintains | Underweight | $40 → $77 |
| 21 Aug 2026 | JP Morgan | Maintains | Underweight | — |
| 20 Aug 2026 | Goldman Sachs | Maintains | Neutral | — |
| 20 Aug 2026 | Goldman Sachs | Maintains | Neutral | $67 → $120 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
MRNA appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 29 Oct 2026, Moderna, Inc. returned +801.9% against +13.1% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 30% of US stocks
Cheaper than 6% of US stocks
Cheaper than 7% of US stocks
Cheaper than 93% of US stocks
Higher than 32% of US stocks
Higher than 41% of US stocks
Higher than 42% of US stocks
Higher than 7% of US stocks
Higher than 4% of US stocks
Higher than 24% of US stocks
Higher than 24% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Moderna, Inc. has a market value of $83.0B and an enterprise value of $79.2B.
Revenue in the twelve months to 30 June 2026: $2.2B. The latest quarter grew 2.1% year on year.
Net income over the same four quarters: −$3.2B, a −142.6% net margin.
Diluted earnings per share, trailing twelve months: $−7.99.
Free cash flow in the twelve months to 30 June 2026: −$1.2B.
Trailing P/E: 25.0×; forward P/E: −45.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Moderna, Inc. employs 4,700 people — $470K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Moderna, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks compares GSK’s Specialty Medicines growth, pipeline and dividend with Moderna’s oncology potential and premium valuation.
Why it matters — The comparison highlights the factors shaping how investors assess Moderna relative to a large-cap biotech peer.
Moderna has recently received considerable attention from users of Zacks.com, and the article says investors should be aware of facts that could affect the stock’s prospects.
Why it matters — MRNA watchers may want to review the factors discussed that could affect the stock’s prospects.
Investors are focused on Moderna’s personalized cancer vaccine candidate after it delivered positive clinical trial data. The stock surged following the August data release but has given up some gains in recent days.
Why it matters — The trial data and recent share-price movement are developments for MRNA watchers tracking investor response to the candidate.
Moderna CEO Stéphane Bancel defended the company’s melanoma data, saying it could improve over time and that competitors cannot easily copy its work.
Why it matters — The comments address the progress of Moderna’s cancer-vaccine data and the difficulty rivals may face in replicating its technology.
Moderna shares rose 4% in morning trading despite a valuation downgrade from William Blair. The excerpt says investors are weighing strong cancer vaccine data against expectations reflected in the share price.
Why it matters — MRNA watchers may note the contrast between positive cancer vaccine data and concerns about the company’s valuation.
The 23 Wall Street analysts covering Moderna, Inc. have a median 12-month price target of $125, with estimates ranging from $45 to $251. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 23 analysts covering Moderna, Inc., 4 rate it a Buy, 16 a Hold and 3 a Sell. Ticker Nerd's systematic factor model ranks Moderna, Inc. 78 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, Moderna, Inc. ranks 78 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).
No one can know that. What the data says: the median 12-month target from 23 analysts implies -43.9% from the last close, and Ticker Nerd's factor model ranks Moderna, Inc. 78 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Moderna, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MRNA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $45 to $251 over the next 12 months.
Moderna, Inc. returned +801.9% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Moderna Inc. is a biotechnology company focused on developing medicines and vaccines based on messenger RNA (mRNA) technology.
The most recent item we track (Zacks Investment Research, 29 Oct 2026): "GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth?". Zacks compares GSK’s Specialty Medicines growth, pipeline and dividend with Moderna’s oncology potential and premium valuation.
Moderna Inc. is a biotechnology company focused on developing medicines and vaccines based on messenger RNA (mRNA) technology. Its commercial portfolio includes respiratory and infectious disease vaccines, while its broader pipeline spans oncology, rare diseases, autoimmune conditions, and other therapeutic areas. Moderna uses its mRNA platform to design products that instruct cells to produce proteins or immune responses relevant to prevention and treatment. The company also works with manufacturing and commercialization capabilities to support product development and distribution across major healthcare markets. Headquartered in Cambridge, Massachusetts, Moderna plays a significant role in the biopharmaceutical industry by advancing a new class of medicines across vaccines and therapeutics.
CEO Mr. Stéphane Bancel M.B.A. · 4,700 employees · United States · https://www.modernatx.com
